

4.0.03 DOC Cmte minutes

VTE Diseases Committee meeting

Date: 29/10/18 & 30/10/18

Location: NICE – London

Minutes: Final



Committee members present:	
Susan Bewley (SB) (Chair)	Present for all
Frances Akor (FA)	Present for all
Michelle Greene (MG)	Present for all
Sam Hare (SH)	Present for all
Daniel Horner (DH)	Present for all
Carol Hooper (CH)	Present for all
Daniel Horner (DH)	Present day 1 from item 2 to part way through item 5, day 1 present for all
Nigel Langford (NL)	Present for all
Terry McCormack (TM)	Present for all
Simon McPherson (SM)	Present for all
Karen Sheares (KS)	Present day 1 from item 2, day 2 present for all
Astrid Ullrich-Boereboom (AU)	Present for all

In attendance:		
Thomas Jarratt (TJ)	NICE – Technical Analyst	Present for all
Marie Harrisingh	NICE – Technical Adviser	
Ben Johnson (BJ)	NICE – Health Economist	Present for all
Justine Karpusheff (JK)	NICE – Guidelines Commissioning Manager	Present for all
Dianne Kitchen (DK)	Expert witness	Present day 1, item 5
Bernadette Li (BL)	NICE – Technical Adviser (HE)	Present day 1, items 1 to 4 and 7, and 8 Present day 2 for all
Judith McBride (JB)	Present day1, item 5	Present day 1, from item 4 to partway

4.0.03 DOC Cmte minutes

		through item 6
Vonda Murray (VM)	NICE – Project Manager	Present for all

Apologies:

Julia Anderson	Committee member
Elizabeth Barrett	NICE – Information Specialist
Hazel Trender	Committee member
Susan Spiers	NICE – Associate Director

Observer:

Sohaib Ashraf	Health Economist	Present day 1 from item 2
Priya Modha	Pharmacy Clinical Fellow	Present day 1
Hannah Nicholas	Health Economist	Present for day 2

Day 1 – Monday 29th October 2018

1. Introductions and guideline committee working

The Chair welcomed the Committee members and attendees to day 1 of the 5th committee meeting on VTE diseases. The Committee members and attendees introduced themselves.

The committee reviewed the minutes from Gcomm 4; Monday 10th September 2018, and these were agreed to be an accurate record. The Chair informed the Committee that apologies had been received from those listed above. The objectives of the meeting were outlined by the Chair.

The DOI register was made available to the Chair and committee. The Chair reviewed the DOI register, a number of new declarations were made, and these are noted below. The DOI's were considered by the Chair. It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The Chair outlined the objectives of the meeting;

- A clinical introduction for 1 of the review question to be presented at Gcomm5
- Evidence presentation and discussion around the pharmaceutical review questions

4.0.03 DOC Cmte minutes

- The Editor outlining her role in the guideline development process
- Expert witness presentation on D-dimer tests

Name	Job title	Declarations of Interest	Type of interest	Decision taken
Astrid Ullrich-Boereboom	Lay member	8 th October 2018 – presented a patient story during a training day for junior doctors. Arranged by the charity thrombosis UK. No expenses/fees	Direct, non-financial	Declare and participate
Karen Sheares	Physician - with a special interest in vascular disease	Presented an update on Pulmonary Hypertension at Peterborough General Hospital 27 Nov 2018.	Direct, financial (travel only)	Declare and participate Not specific to any topic covered in the scope of the guideline
Terry McCormack	GP	8 th November visiting lecturer, University of Warwick. Fees received cover expenses. Topic of lecture Atrial Fibrillation	Direct, financial (Expenses only)	Declare and participate Not specific to any topic covered in the scope of the guideline.
Terry McCormack	GP	17 th November, presented a hypertension case study, at a conference at University of Nottingham. No fee/expenses paid	Direct, non-financial	Declare and participate Not specific to any topic covered in the scope of the guideline.

Item 2

RQ6.1 What factors determine the optimum duration of pharmacological treatment for DVT or PE in people with VTE?

4.0.03 DOC Cmte minutes

- Clinical introduction for RQ6.1

Item 2

KS provided a clinical introduction to the committee on the factors which determine the optimum duration of pharmacological treatment for DVT or PE in people with VTE. Her presentation included an overview of the aims of pharmacological intervention, VTE recurrence rates and a summary of the prediction tools used to estimate the risk of VTE recurrence. KS also talked about bleeding risk scores. The Chair thanked KS for her presentation. The committee asked a number of questions.

Item 3

RQ 3.1: What is the clinical and cost effectiveness of different pharmacological treatments for people with a confirmed diagnosis of DVT?

RQ 3.2: What is the clinical and cost effectiveness of different pharmacological treatments for people with a confirmed diagnosis of PE?

RQ 1.3: What is the clinical and cost effectiveness of different pharmacological treatments for people with suspected DVT prior to confirmed diagnosis?

RQ 2.4: What is the clinical and cost effectiveness of different pharmacological treatments for people with suspected PE prior to confirmed diagnosis?

- Study overview

Item 3

TJ provided a summary of the search protocol, including the inclusion and exclusion criteria. The committee were advised of the results of the database search and sift. The evidence presented was for the clinical effectiveness of different pharmacological treatments for the treatment of people with a confirmed diagnosis or prior to diagnosis of DVT or PE only as no studies were found that included people with suspected DVT or PE.

Item 4

- **The role of the Editor**

Item 4

JB explained to the committee the role of the Editor in developing guidelines. Also the importance of clear recommendations, and how clear recommendations can be achieved.

Item 5

RQ 1.2: In people with suspected DVT, what is the diagnostic accuracy of point-of-care D-dimer tests compared with laboratory tests to identify DVT?

RQ 3.1: In people with suspected PE, what is the diagnostic accuracy of point-of-care D-dimer tests compared with laboratory tests to identify PE?

- Expert witness presentation

4.0.03 DOC Cmte minutes

<ul style="list-style-type: none">• Questions and answers
<p>Item 5</p> <p>The Chair introduced and welcomed DK to the committee meeting. DK provided an overview of D-dimer tests and the diagnostic accuracy of point-of-care D-dimer laboratory tests to identify PE or VTE. The committee asked DK a number of questions. The Chair thanked DK for her presentation and for answering committee queries.</p>
<p>Item 6</p> <p>RQ1.2 & RQ3.1</p> <ul style="list-style-type: none">• Committee discussion
<p>Item 6</p> <p>The committee discussed the information that was provided by the expert witness and edited their existing recommendations for these questions based on it.</p>
<p>Item 7</p> <p>RQ 3.1, RQ 3.2, RQ 1.3 and RQ 2.4</p> <ul style="list-style-type: none">• Clinical evidence presentation and discussion
<p>Item 7</p> <p>TJ continued to present the clinical evidence for the pharmaceutical questions. The committee discussed the evidence and asked the NICE technical team questions.</p>
<p>Item 8</p> <p>Next steps</p>
<p>Item 8</p> <p>The Chair thanked everyone for their contribution to the meeting, and reminded the committee of the start time for day 2 of the meeting.</p>

4.0.03 DOC Cmte minutes

Day 2 Tuesday 19 June 2018:

Item 1

Meeting open

The Chair welcomed the Committee members and attendees to the 2nd day of the 5th meeting on VTE diseases. The Committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received from those listed above.

The Chair asked everyone present to declare any new interests, but no new declaration of interests had arisen overnight. Having reviewed the registry of previous declarations, the chair noted that the interests declared did not prevent any of the attendees from fully participating in the meeting.

The Chair then outlined the objectives of the day, which included:

- Continuation of the presentation of evidence and discussion around the pharmaceutical review questions
- Health economic model presentation
- Making recommendations

Item 2

RQ 3.1, RQ 3.2, RQ 1.3, RQ 2.4 continued

- Clinical evidence presentation and discussion

Item 2

TJ presented the results of network meta-analyses examining the clinical effectiveness of different pharmacological treatments for the treatment of people with a confirmed diagnosis of DVT or PE.

Item 3

- Health Economics literature review
- Health Economics modelling

Item 3

BJ provided an overview of the published economic evidence, before moving onto the presentation of the results from the economic model.

Item 4

- Health Economics modelling continued

4.0.03 DOC Cmte minutes

Item 4

BJ explained where further data was required for the model and asked the committee for their input.

Item 5

- Draft recommendations

Item 5

The committee drafted recommendations for the pharmacological treatment of people with confirmed DVT or PE. The drafting of recommendations will be continued at the next meeting when additional evidence will be presented for extended pharmacological treatment and for pharmacological treatment of people with cancer.

Item 6

AOB

Item 6

No other business

Item 7

Summary and next steps

Item 7

The Chair thanked the committee for their input into the 2 day meeting, and reminded the committee of the next committee meeting date, and location Monday 17th December 2018, London